Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

Abstract Background Clinically-available biomarkers to identify the fraction of patients with small cell lung cancer (SCLC) who respond to immune-checkpoint inhibitors (ICIs) are lacking. High nonsynonymous tumor mutational burden (TMB), as assessed by whole exome sequencing, correlates with improve...

Full description

Bibliographic Details
Main Authors: Biagio Ricciuti, Sasha Kravets, Suzanne E. Dahlberg, Renato Umeton, Adem Albayrak, Safiya J. Subegdjo, Bruce E. Johnson, Mizuki Nishino, Lynette M. Sholl, Mark M. Awad
Format: Article
Language:English
Published: BMJ Publishing Group 2019-03-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Tumor mutational burden
Immunotherapy
SCLC
Online Access:http://link.springer.com/article/10.1186/s40425-019-0572-6

Internet

http://link.springer.com/article/10.1186/s40425-019-0572-6

Similar Items